Discontinued — last reported Q4 '24

Other

Business Combination, Contingent Consideration, Liability, Noncurrent

Pfizer Business Combination, Contingent Consideration, Liability, Noncurrent increased by 14.8% to $1.95B in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ4 2024
Metric ID: other_business_combination_contingent_consideration_liab_1ff57c

Historical Data

2 periods
 Q4 '25Q1 '26
Value$1.70B$1.95B
QoQ Change—+14.8%
Range$1.70B – $1.95B

Frequently Asked Questions

What is Pfizer's business combination, contingent consideration, liability, noncurrent?
Pfizer (PFE) reported business combination, contingent consideration, liability, noncurrent of $1.95B in Q1 2026.